Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo

Cell Stem Cell

Volumn 22, Issue 4, 2018, Pages 501-513.e7

  Kooreman, Nigel G ^a,b   Kim, Youngkyun ^a,d   de Almeida, Patricia E ^a   Termglinchan, Vittavat ^a   Diecke, Sebastian ^e,f,g   Shao, Ning Yi ^a   Wei, Tzu Tang ^a   Yi, Hyoju ^a,d   Dey, Devaveena ^a   Nelakanti, Raman ^a   Brouwer, Thomas P ^a,b   Paik, David T ^a   Sagiv Barfi, Idit ^c   Han, Arnold ^a   Quax, Paul H A ^b   Hamming, Jaap F ^b   Levy, Ronald ^c   Davis, Mark M ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c STANFORD CANCER INSTITUTE   (United States)

^d The Catholic University of Korea   (South Korea)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^g BERLIN INSTITUTE OF HEALTH   (Germany)

Author keywords

adjuvant therapy; breast cancer; immune profiling; immunotherapy; melanoma; mesothelioma; metastases; pluripotent stem cells; prophylactic vaccination; shared epitopes

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G;

ADOPTIVE TRANSFER; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; YOUNG ADULT; ANIMAL; BREAST TUMOR; CYTOLOGY; IMMUNOLOGY; MESOTHELIOMA;

ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; FEMALE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MELANOMA; MESOTHELIOMA; MICE;

EID: 85042036923     PISSN: 19345909     EISSN: 18759777     Source Type: Journal    
DOI: 10.1016/j.stem.2018.01.016     Document Type: Article

References (54)

1. Anders, S., Huber, W., Differential expression analysis for sequence count data. Genome Biol., 11, 2010, R106.
2. Anders, S., McCarthy, D.J., Chen, Y., Okoniewski, M., Smyth, G.K., Huber, W., Robinson, M.D., Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. Nat. Protoc. 8 (2013), 1765–1786.
3. Anders, S., Pyl, P.T., Huber, W., HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31 (2015), 166–169.
4. Ben-Porath, I., Thomson, M.W., Carey, V.J., Ge, R., Bell, G.W., Regev, A., Weinberg, R.A., An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40 (2008), 499–507.
5. Bock, C., Kiskinis, E., Verstappen, G., Gu, H., Boulting, G., Smith, Z.D., Ziller, M., Croft, G.F., Amoroso, M.W., Oakley, D.H., et al. Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144 (2011), 439–452.
6. Brewer, B.G., Mitchell, R.A., Harandi, A., Eaton, J.W., Embryonic vaccines against cancer: an early history. Exp. Mol. Pathol. 86 (2009), 192–197.
7. Bruggner, R.V., Bodenmiller, B., Dill, D.L., Tibshirani, R.J., Nolan, G.P., Automated identification of stratifying signatures in cellular subpopulations. Proc. Natl. Acad. Sci. USA 111 (2014), E2770–E2777.
8. Chang, G., Gao, S., Hou, X., Xu, Z., Liu, Y., Kang, L., Tao, Y., Liu, W., Huang, B., Kou, X., et al. High-throughput sequencing reveals the disruption of methylation of imprinted gene in induced pluripotent stem cells. Cell Res. 24 (2014), 293–306.
9. Chen, J.Y., Tang, Y.A., Huang, S.M., Juan, H.F., Wu, L.W., Sun, Y.C., Wang, S.C., Wu, K.W., Balraj, G., Chang, T.T., et al. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 71 (2011), 473–483.
10. Chung, A.S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., Vernes, J.M., Jiang, Z., Meng, Y.G., Peale, F.V., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19 (2013), 1114–1123.
11. Churko, J., Lee, J., Ameen, M., Gu, M., Venkaasubramanian, M., Diecke, S., Sallam, K., Im, H., Wang, G., Gold, J.D., et al. Transcriptomic and epigenomic differences in human induced pluripotent stem cells generated from six reprogramming methods. Nat. Biomed. Eng. 1 (2017), 826–837.
12. Consortium, E.P., ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol., 9, 2011, e1001046.
13. de Almeida, P.E., Meyer, E.H., Kooreman, N.G., Diecke, S., Dey, D., Sanchez-Freire, V., Hu, S., Ebert, A., Odegaard, J., Mordwinkin, N.M., et al. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat. Commun., 5, 2014, 3903.
14. Diecke, S., Lu, J., Lee, J., Termglinchan, V., Kooreman, N.G., Burridge, P.W., Ebert, A.D., Churko, J.M., Sharma, A., Kay, M.A., Wu, J.C., Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency. Sci. Rep., 5, 2015, 8081.
15. Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., Geilich, M., Winkels, G., Traggiai, E., Casati, A., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40 (2010), 22–35.
16. Dooms, H., Abbas, A.K., Life and death in effector T cells. Nat. Immunol. 3 (2002), 797–798.
17. Evans, M.S., Chaurette, J.P., Adams, S.T. Jr., Reddy, G.R., Paley, M.A., Aronin, N., Prescher, J.A., Miller, S.C., A synthetic luciferin improves bioluminescence imaging in live mice. Nat. Methods 11 (2014), 393–395.
18. Gajewski, T.F., Schreiber, H., Fu, Y.X., Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (2013), 1014–1022.
19. Galvan, D.L., O'Neil, R.T., Foster, A.E., Huye, L., Bear, A., Rooney, C.M., Wilson, M.H., Anti-tumor effects after adoptive transfer of IL-12 transposon-modified murine splenocytes in the OT-I-melanoma mouse Model. PLoS ONE, 10, 2015, e0140744.
20. Ghosh, Z., Huang, M., Hu, S., Wilson, K.D., Dey, D., Wu, J.C., Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. Cancer Res. 71 (2011), 5030–5039.
21. Gilkeson, G.S., Conover, J., Halpern, M., Pisetsky, D.S., Feagin, A., Klinman, D.M., Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. J. Immunol. 161 (1998), 3890–3895.
22. Goldstein, M.J., Varghese, B., Brody, J.D., Rajapaksa, R., Kohrt, H., Czerwinski, D.K., Levy, S., Levy, R., A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 117 (2011), 118–127.
23. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
24. Harrow, J., Frankish, A., Gonzalez, J.M., Tapanari, E., Diekhans, M., Kokocinski, F., Aken, B.L., Barrell, D., Zadissa, A., Searle, S., et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 22 (2012), 1760–1774.
25. He, D., Li, H., Yusuf, N., Elmets, C.A., Li, J., Mountz, J.D., Xu, H., IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J. Immunol. 184 (2010), 2281–2288.
26. Inoue, H., Watanabe, A., Sakamoto, C., Narusawa, M., Hiramoto, T., Miyamoto, S., Inoue, M., Takayama, K., Hasegawa, M., Nakanishi, Y., Vaccination With Irradiated Induced Pluripotent Stem Cells Genetically Engineered To Produce GM-CSF Confers Potent T Cells-Mediated Antitumor Immunity. Blood, 122(21), 2013, 4492 Accessed February 01, 2018. Retrieved from http://www.bloodjournal.org/content/122/21/4492.
27. Kim, D., Langmead, B., Salzberg, S.L., HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12 (2015), 357–360.
28. Kocatürk, B., Versteeg, H.H., Orthotopic injection of breast cancer cells into the mammary fat pad of mice to study tumor growth. J. Vis. Exp., 96, 2015, 51967.
29. Kooreman, N.G., Wu, J.C., Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging. J. R. Soc. Interface 7:Suppl 6 (2010), S753–S763.
30. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
31. Lee, A.S., Tang, C., Rao, M.S., Weissman, I.L., Wu, J.C., Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19 (2013), 998–1004.
32. Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah, N.N., et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385 (2015), 517–528.
33. Li, Y., Zeng, H., Xu, R.H., Liu, B., Li, Z., Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. Stem Cells 27 (2009), 3103–3111.
34. Mallon, B.S., Chenoweth, J.G., Johnson, K.R., Hamilton, R.S., Tesar, P.J., Yavatkar, A.S., Tyson, L.J., Park, K., Chen, K.G., Fann, Y.C., McKay, R.D., StemCellDB: the human pluripotent stem cell database at the National Institutes of Health. Stem Cell Res. (Amst.) 10 (2013), 57–66.
35. Mallon, B.S., Hamilton, R.S., Kozhich, O.A., Johnson, K.R., Fann, Y.C., Rao, M.S., Robey, P.G., Comparison of the molecular profiles of human embryonic and induced pluripotent stem cells of isogenic origin. Stem Cell Res. (Amst.) 12 (2014), 376–386.
36. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
37. Maus, M.V., Grupp, S.A., Porter, D.L., June, C.H., Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123 (2014), 2625–2635.
38. Mestas, J., Hughes, C.C., Of mice and not men: differences between mouse and human immunology. J. Immunol. 172 (2004), 2731–2738.
39. Mor, G., Singla, M., Steinberg, A.D., Hoffman, S.L., Okuda, K., Klinman, D.M., Do DNA vaccines induce autoimmune disease?. Hum. Gene Ther. 8 (1997), 293–300.
40. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
41. Mukherjee, P., Pathangey, L.B., Bradley, J.B., Tinder, T.L., Basu, G.D., Akporiaye, E.T., Gendler, S.J., MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model. Vaccine 25 (2007), 1607–1618.
42. Naas, T., Ghorbani, M., Soare, C., Scherling, N., Muller, R., Ghorbani, P., Diaz-Mitoma, F., Adoptive transfer of splenocytes to study cell-mediated immune responses in hepatitis C infection using HCV transgenic mice. Comp. Hepatol., 9, 2010, 7.
43. Nelakanti, R.V., Kooreman, N.G., Wu, J.C., Teratoma formation: a tool for monitoring pluripotency in stem cell research. Curr. Protoc. Stem Cell Biol., 32, 2015 4A.8.1–4A.8.17.
44. Numasaki, M., Fukushi, J., Ono, M., Narula, S.K., Zavodny, P.J., Kudo, T., Robbins, P.D., Tahara, H., Lotze, M.T., Interleukin-17 promotes angiogenesis and tumor growth. Blood 101 (2003), 2620–2627.
45. Palena, C., Abrams, S.I., Schlom, J., Hodge, J.W., Cancer vaccines: preclinical studies and novel strategies. Adv. Cancer Res. 95 (2006), 115–145.
46. Qiu, P., Simonds, E.F., Bendall, S.C., Gibbs, K.D. Jr., Bruggner, R.V., Linderman, M.D., Sachs, K., Nolan, G.P., Plevritis, S.K., Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat. Biotechnol. 29 (2011), 886–891.
47. Sodhi, A., Tandon, P., Sarna, S., Adoptive transfer of immunity against solid fibrosarcoma in mice with splenocytes and peritoneal exudate cells obtained after in vitro sensitization and in vivo immunization with cis-dichlorodiamine platinum(II) treated fibrosarcoma cells. Arch. Geschwulstforsch. 55 (1985), 47–61.
48. Soldner, F., Hockemeyer, D., Beard, C., Gao, Q., Bell, G.W., Cook, E.G., Hargus, G., Blak, A., Cooper, O., Mitalipova, M., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009), 964–977.
49. Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
50. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
51. Torcellan, T., Hampton, H.R., Bailey, J., Tomura, M., Brink, R., Chtanova, T., In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors. Proc. Natl. Acad. Sci. USA 114 (2017), 5677–5682.
52. Yaddanapudi, K., Mitchell, R.A., Putty, K., Willer, S., Sharma, R.K., Yan, J., Bodduluri, H., Eaton, J.W., Vaccination with embryonic stem cells protects against lung cancer: is a broad-spectrum prophylactic vaccine against cancer possible?. PLoS ONE, 7, 2012, e42289.
53. Zhao, T., Zhang, Z.N., Rong, Z., Xu, Y., Immunogenicity of induced pluripotent stem cells. Nature 474 (2011), 212–215.
54. Zou, W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5 (2005), 263–274.